Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: desvenlafaxine succinate

« Back to Dashboard
Desvenlafaxine succinate is the generic ingredient in two branded drugs marketed by Alembic Pharms Ltd, Lupin Ltd, Mylan Pharms Inc, Sandoz Inc, and Wyeth Pharms Inc, and is included in five NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has sixty-two patent family members in thirty-two countries.

There are twelve drug master file entries for desvenlafaxine succinate. Six suppliers are listed for this compound.

Summary for Generic Name: desvenlafaxine succinate

Tradenames:2
Patents:2
Applicants:5
NDAs:5
Drug Master File Entries: see list12
Suppliers / Packaging: see list17

Clinical Trials for: desvenlafaxine succinate

Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women
Status: Recruiting Condition: Major Depressive Disorder; Menopausal Staging and Vasomotor Symptoms (for Females)

Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females
Status: Completed Condition: Healthy

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Status: Completed Condition: Major Depressive Disorder

Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder
Status: Completed Condition: Major Depressive Disorder

Desvenlafaxine in Opioid-Dependent Patients
Status: Recruiting Condition: Depression; Opioid Dependence; Methadone Treatment

Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
Status: Completed Condition: Major Depressive Disorder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992-002Feb 29, 2008RXYes<disabled><disabled>
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992-001Feb 29, 2008RXYes6,673,838<disabled>Y <disabled>
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992-002Feb 29, 2008RXYes8,269,040<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: desvenlafaxine succinate

Country Document Number Publication Date
Poland396568Feb 13, 2012
Norway20014816Dec 04, 2001
Portugal1466889Jul 02, 2008
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc